Skip to main content

BreastView

AI‑powered mammography assistant for earlier detection

BreastView detects suspicious lesions on mammograms, helping radiologists make faster, more confident decisions, seamlessly integrated into their daily workflow.

Detect breast cancer earlier

BreastView is an AI solution that analyzes mammograms to assist radiologists by highlighting suspicious breast lesions within their routine workflow. It detects soft‑tissue findings such as masses, distortions, and asymmetries, as well as breast microcalcifications, and provides both a malignancy score and breast density assessment.

Discover BreastView at work

Soft tissue lesions
Calcifications

Indication

63 y.o. patient presenting as part of organized screening.

Results

BreastView detected a lesion that was a non-specific infiltrating carcinoma.

Indication

56 y.o patient presenting as part of organized screening.

Results

BreastView detected a benign cyst and micro-calcifications that were a ductal carcinoma in situ (DCIS).

A safety net built to increase radiologist’s confidence

Sensitivity of
85%
for cancer detection¹
Specificity of
93%
for cancerous lesions²
Increase of
93%
in cancer detected with BreastView assistance³

Boost your workflow with the power of advanced integrations

Designed with radiologists, our workflow integrations blend effortlessly into daily routines, enhancing speed, clarity, and confidence at every step.

AI-powered Worklist

Worklist now highlights AI results, findings, and automatically prioritizes urgent patient cases.

Shadow Mode

AI results appear on native images, where radiologists can review, accept, or reject, all within their workflow.

Part of Gleamer Copilot

Gleamer Copilot is the all-in-one AI platform that supports radiologists from image to report. It combines powerful detection tools, smart measurements, and structured reporting to boost accuracy and efficiency, all seamlessly integrated into your workflow.

Already implemented in
+2500
Clinical sites
We analyze
+45M
Patients/year
Worldwide presence in
+45
Countries

¹BreastView has a sensitivity of 85% on biopsy-proven malignant lesions.

²BreastView has a 93% specificity for cancerous lesions.

³Sensitivity of all radiologists without AI 59.6%, sensitivity of all radiologists with AI 75.5%

For the latest regulatory information, refer to: https://www.gleamer.ai/privacy-policy